S. hominis A 9 Product for Eczema (TIME-1 Trial)

"Our assessment of S. hominis A 9 Product's safety is relatively low, with a score of 1 out of 3 due to the preliminary nature of its clinical trials and the lack evidence for efficacy."

"This medical trial is recruiting for 20 patients between 18 and 80 years old, suffering from infantile eczema. Eligible candidates must have 21 cm^2 of both lesional and non-lesional skin on their right and left ventral arms (which may be broken up into smaller areas). Additionally, the Investigator Global Assessment score should register as moderate or greater, while body surface area needs to fall within 1.26 m^2 to 2.25 m^2 according to Mostellar BSA Calculator calculations."

"The information hosted on clinicaltrials.gov indicates that recruitment for this medical project is open to the public. It was originally posted on July 18th 2022 and underwent its most recent modification three days later."

"The requirements for this trial stipulate that prospective participants must be aged between 18 and 80. Meanwhile, there are separate trials specifically designed to evaluate younger or older demographics with 101 and 165 studies respectively."

"That is correct. According to the records accessible on clinicaltrials.gov, this trial was first posted on July 18th and has since been revised for accuracy. Currently, 20 patients are needed from a single medical facility."